LifeStance Health Group (NASDAQ:LFST) Reaches New 52-Week High After Analyst Upgrade

LifeStance Health Group, Inc. (NASDAQ:LFST)’s stock price hit a new 52-week high during mid-day trading on Friday after Barclays raised their price target on the stock from $13.00 to $15.00. Barclays currently has an overweight rating on the stock. LifeStance Health Group traded as high as $13.27 and last traded at $13.00, with a volume of 5941430 shares. The stock had previously closed at $12.62.

A number of other analysts also recently weighed in on the company. Wall Street Zen downgraded LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 5th. Canaccord Genuity Group raised their price target on LifeStance Health Group from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. boosted their price target on LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. BTIG Research upped their price objective on shares of LifeStance Health Group from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. Finally, Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.88.

Insider Activity

In other LifeStance Health Group news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.62, for a total value of $144,890,858.34. Following the sale, the insider owned 98,101,407 shares of the company’s stock, valued at approximately $1,041,836,942.34. This trade represents a 12.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CTO Vukasin Paunovich sold 44,394 shares of LifeStance Health Group stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.85, for a total value of $481,674.90. Following the completion of the transaction, the chief technology officer owned 247,446 shares in the company, valued at approximately $2,684,789.10. The trade was a 15.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 14,671,917 shares of company stock valued at $155,493,415 in the last three months. Company insiders own 3.50% of the company’s stock.

LifeStance Health Group News Roundup

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Barclays raised its price target for LifeStance Health Group from $13 to $15 and maintained an “overweight” rating, implying further upside from the stock’s recent level. Barclays price target report
• Positive Sentiment: Zacks highlighted LFST as a strong momentum candidate, reinforcing investor interest after the shares’ substantial appreciation over the past year. Zacks momentum stock analysis
• Positive Sentiment: The company’s latest quarterly results showed strong operating momentum: revenue increased 26.1% year over year to $435.4 million, while adjusted earnings of $0.06 per share exceeded expectations of $0.03. The company is also projected to remain profitable for the full year.
• Neutral Sentiment: LifeStance announced a secondary offering alongside a share repurchase program. The repurchase could help absorb some of the shares being offered and support the stock, although the overall effect depends on the offering size and terms. LifeStance secondary offering and share repurchase announcement
• Neutral Sentiment: Brokerages collectively rate LFST a “Moderate Buy,” suggesting generally favorable expectations but not unanimous conviction.
• Negative Sentiment: The secondary offering may create additional share supply and weigh on the stock in the near term, particularly after its sharp run-up. The stock also trades at a high valuation—roughly 100 times earnings—leaving it sensitive to changes in growth expectations.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Assetmark Inc. raised its stake in LifeStance Health Group by 17.0% during the first quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after acquiring an additional 1,367 shares in the last quarter. Allworth Financial LP boosted its stake in shares of LifeStance Health Group by 7.7% in the 2nd quarter. Allworth Financial LP now owns 26,532 shares of the company’s stock valued at $284,000 after purchasing an additional 1,889 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of LifeStance Health Group by 1.6% during the 4th quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock valued at $885,000 after purchasing an additional 1,966 shares during the last quarter. Vident Advisory LLC grew its holdings in shares of LifeStance Health Group by 12.7% during the 2nd quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after purchasing an additional 2,447 shares during the last quarter. Finally, Xponance LLC increased its position in LifeStance Health Group by 26.4% during the 4th quarter. Xponance LLC now owns 13,144 shares of the company’s stock worth $93,000 after purchasing an additional 2,745 shares in the last quarter. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Stock Performance

The firm has a market capitalization of $4.96 billion, a price-to-earnings ratio of 99.78 and a beta of 1.22. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.18. The stock’s 50-day moving average is $11.67 and its 200-day moving average is $9.00.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $435.35 million for the quarter, compared to analyst estimates of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The company’s quarterly revenue was up 26.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.01) earnings per share. On average, analysts predict that LifeStance Health Group, Inc. will post 0.16 EPS for the current fiscal year.

About LifeStance Health Group

LifeStance Health Group, Inc is a behavioral health care company that provides outpatient mental health services through in-person and virtual appointments. Its platform connects patients with psychiatrists, psychologists, psychiatric nurse practitioners, therapists and other licensed clinicians.

The company offers services that may include psychotherapy, psychiatric evaluations, medication management and treatment for conditions such as anxiety, depression, attention-deficit/hyperactivity disorder and other behavioral health needs.